December 2012 | Oncology & Biotech News

Mark G. Kris, MD, Discusses Emerging Targets and Treatments for Lung Cancer

January 04, 2013

Mark G. Kris, MD, offers insight into NSCLC related topics, including emerging therapeutic targets, the optimal application of TKIs, strategies for patients with poor performance status, maintenance therapies, and the treatment pipeline.

Emerging Agents for the Treatment of Ovarian Cancer

December 22, 2012

Although the association between VEGF and ovarian cancer has been known for quite some time, researchers are still struggling to use drugs that inhibit VEGF and angiogenesis in patients with the disease.

Controlling Progression in Patients With Metastatic Colorectal Cancer

December 21, 2012

The prognosis for patients with colorectal cancer has benefited greatly from the advent of advances in chemotherapy and new agents, with nearly threefourths of stage I patients surviving for at least 5 years after diagnosis.

Study Results May Change Treatment Standard for Patients Receiving Transplants From Unrelated Donors

December 21, 2012

Patients receiving transplants from unrelated donors to treat various hematologic malignancies may benefit more from receiving adult stem cells harvested from bone marrow rather than peripheral-blood stem cells (the current standard).

Cardiac Risks Higher in Older Women Receiving Adjuvant Trastuzumab

December 21, 2012

A retrospective study of older women with early-stage breast cancer who received adjuvant trastuzumab alone or in combination with anthracyclines has revealed a higher incidence of heart failure and cardiomyopathy.